by | Apr 16, 2024 | Publications
Open Life Sci. 2024 Apr 12;19(1):20220848. doi: 10.1515/biol-2022-0848. eCollection 2024. ABSTRACT Bortezomib (BTZ), a proteasome inhibitor, is a promising therapeutic option for multiple myeloma (MM) patients. However, drug resistance often occurs, leading to disease...
by | Apr 16, 2024 | Publications
Leuk Lymphoma. 2024 Apr 16:1-8. doi: 10.1080/10428194.2024.2340052. Online ahead of print. ABSTRACT There is limited knowledge regarding the prevalence of geriatric impairments and frailty among patients with multiple myeloma (MM) in a real-world setting. This study...
by | Apr 16, 2024 | Publications
Cytotherapy. 2024 Mar 29:S1465-3249(24)00572-3. doi: 10.1016/j.jcyt.2024.03.481. Online ahead of print. ABSTRACT BACKGROUND AIMS: Chimeric antigen receptor-T (CAR-T) cells have exhibited remarkable efficacy in treating refractory or relapsed multiple myeloma (R/R MM)....
by | Apr 16, 2024 | Publications
Blood Cancer J. 2024 Apr 15;14(1):65. doi: 10.1038/s41408-024-01046-2. NO ABSTRACT PMID:38622134 | DOI:10.1038/s41408-024-01046-2
by | Apr 16, 2024 | Publications
Leukemia. 2024 Apr 15. doi: 10.1038/s41375-024-02185-y. Online ahead of print. NO ABSTRACT PMID:38622290 | DOI:10.1038/s41375-024-02185-y
by | Apr 16, 2024 | Publications
Med Eng Phys. 2024 Apr;126:104147. doi: 10.1016/j.medengphy.2024.104147. Epub 2024 Mar 11. ABSTRACT BACKGROUND: Two main problems examining the mechanism of cancer progression in the tissues using the computational models are lack of enough knowledge on the effective...